オプティアム・バイオテクノロジーズ株式会社
5 known investors
Optieum develops next-generation CAR-T cell therapies using a proprietary CAR discovery platform to optimize immune cell activation for treating solid tumors and hematological malignancies. The company engineers precision CAR constructs to enhance T-cell therapeutic efficacy.
Investors · 5
Competitors · 5
by search overlap
Alterome Therapeutics, Inc.3 shared keywordsAlterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Akadeum Life Sciences3 shared keywordsAkadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products. The company serves research, clinical trial, and therapeutic manufacturing environments requiring regulated cell separation products.
Aikium3 shared keywordsAikium combines deep learning with large-scale wet-lab experimentation to design and screen protein libraries, aiming to develop protein therapeutics for hard-to-treat targets such as GPCRs and ion channels. The company focuses on drug discovery for parts of the human proteome that conventional antibodies and small molecules cannot address.
Epirium3 shared keywordsEpirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy. The company's lead compound, EPM-01, is in Phase 1 clinical development for Becker muscular dystrophy.
Companies competing with オプティアム・バイオテクノロジーズ株式会社 for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does オプティアム・バイオテクノロジーズ株式会社 do?
- Optieum develops next-generation CAR-T cell therapies using a proprietary CAR discovery platform to optimize immune cell activation for treating solid tumors and hematological malignancies. The company engineers precision CAR constructs to enhance T-cell therapeutic efficacy.
- Who are オプティアム・バイオテクノロジーズ株式会社's investors?
- オプティアム・バイオテクノロジーズ株式会社's investors include Hiroshima Venture Capital Co. Ltd., Iyogin Capital, Kobe University Capital, UntroD Capital, Vision Incubate.